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On December 13, 2007, Merck, the 
manufacturer of Haemophilus influenzae 
type b (Hib) vaccine, announced a voluntary 
recall of certain lots of two Hib products, 
PedvaxHIB (monovalent Hib vaccine) and 
Comvax (Hib/hepatitis B vaccine).  This 
recall has resulted in a disruption of vaccine 
supply in the United States.   
The interim recommendations for the use of 
Hib-containing vaccines are as follows:  The 
CDC, in consultation with the Advisory 
Committee on Immunization Practices 
(ACIP), the American Academy of Family 
Physicians (AAFP) and the American 
Academy of Pediatrics (AAP), recommends 
that providers temporarily defer 
administering the routine Hib vaccine 
booster dose administered at age 12-15 
months except to children in specific high 
risk groups.   
Children in these high risk groups are at 
increased risk for invasive Hib disease and  
include those with asplenia, sickle cell 
disease, human immunodeficiency virus 
infection, and certain other immunodeficiency 
syndromes and malignant neoplasms.   
American Indian/Alaska Native (AI/AN) 
children also are at increased risk for Hib 
disease, particularly in the first 6 months of 
life.  CDC recommends that providers 
continue to vaccinate these high risk children 
with available Hib conjugate vaccines 
according to the routinely recommended 
schedules, including the 12-15 month 
booster dose.  Continued on page 2 
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Changes to the 2008 Childhood Immunization Schedule 
The Recommended 
Immunization Schedules for 
Persons 0-6 and 7-18 and 
the Catch-up Immunization 
Schedule for 2008 have 
been approved by the ACIP, 
AAFP, and AAP.  
The ACIP annually 
publishes a recommended 
immunization schedule for persons aged 0-
18 years to reflect changes in vaccine 
formulations and current recommendations 
for the use of licensed vaccines. Changes to 
the previous schedule include:  
• The pneumococcal conjugate vaccine 
(PCV) footnote reflects updated 
recommendations for incompletely 
vaccinated children aged 
24-59 months, including 
those with underlying 
medical conditions.  
• Recommendations for 
use of the live attenuated 
influenza  vaccine (LAIV) 
now include healthy children 
as young as 2 years of age. 
LAIV should not be administered to 
children aged <5 years with recurrent  
wheezing. Children aged <9 years who are  
receiving influenza vaccine for the first 
time or who were vaccinated for the first 
time last season, but only received 1 dose, 
should have 2 doses of vaccine, at least 4 
weeks apart.  Continued on page 3 
Updated Childhood Immunization 
Schedule for 2008 
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All Hib products are equally effective after 
completion of the primary series. 
However, the administration of 
PedvaxHIB vaccine leads to a more rapid 
seroconversion to protective antibody 
concentrations within the first 6 months of 
life.  CDC recommends that providers 
who currently use PedvaxHIB containing 
vaccines (PedvaxHIB and Comvax) to 
serve predominantly AI/AN children in 
AI/AN communities continue to use only 
PedvaxHIB containing vaccines not 
affected by the recall and vaccinate 
according to the routinely recommended 
schedules, including the 12-15 month 
booster dose.  PedvaxHIB (if available) or 
ActHIB may be used for the booster 
doses for these children during this 
shortage. 
Short-term deferral of the booster dose 
among children aged 12-15 months is not 
likely to result in an increased risk for Hib 
disease because of continued protection 
of children with the primary series and the 
low level of nasopharyngeal carriage and 
transmission achieved in the United 
States by the Hib immunization program.  
Providers should register and track 
children for whom the booster dose is 
deferred to facilitate recalling them for 
vaccination when supply improves. 
The full Morbidity and Mortality Weekly 
Report (MMWR) regarding Hib deferral is 
available at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/
mm5650a4.htm 
Deferral of Booster Dose and Hib Waiver, continued 
IMMUNIZATION UPDATE: THE IOWA IMMUNIZATION PROGRAM NEWSLETTER APRIL 2008 
Don’t forget the hepatitis B!   
Remember that Comvax is a 
combination Hib and hepatitis B 
vaccine.  If you have a child who is 
scheduled to receive the second 
Comvax at 4 months of age, be sure to 
administer a monovalent hepatitis B and 
ActHIB.  If the child is scheduled to 
receive the final dose of Comvax at 12 
months, administer monovalent 
hepatitis B and defer the HIB dose until 
further notice.  
Hib Waiver  
Due to the deferral of the booster dose, 
IDPH has implemented a temporary, 
limited waiver of the provision of 641 
Iowa Administrative Code  (IAC) 7.4(1) 
requiring administration of the final dose 
of Hib vaccine on or after 12 months of 
age.  This waiver will prevent children 
from being excluded from licensed 
childcare centers because of their 
inability to obtain the final dose of Hib 
vaccine on or after 12 months of age.  
This waiver is applicable to all Iowa 
children and is in effect from December 
19, 2007, through December 31, 2008. 
A copy of this waiver is available on our 
Web page under “Current Immunization 
News”: 
http://www.idph.state.ia.us/adper/immunizati
on.asp 
If you have questions regarding these 
recommendations please contact the 
Iowa Immunization Program at 1-800-
831-6293, ext. 2 for Terri Thornton, or 
ext. 7 for Bridget Konz. 
How to Complete the Hib Series with ActHIB: 
PedvaxHIB and Comvax are recommended as a 2-dose primary series (at ages 2 
and 4 months), whereas ActHIB is recommended as a 3-dose primary series (at ages 
2, 4, and 6 months).  If brands of vaccine are changed during the primary series, 
a 3 dose primary series is required (2, 4 and 6 month of age).   
• If only 1 dose of PedvaxHIB vaccine or Comvax has been administered at 2 
months of age, the primary series may be completed with 2 additional doses of 
ActHIB vaccine at 4 and 6 months of age 
• If a child was given 1 dose of ActHIB at 2 months of age and 1 dose of Pedvax-
HIB vaccine or Comvax vaccine at 4 months of age, the primary series may be 
completed with 1 additional dose of ActHIB vaccine at 6 months of age 
• If 2 doses of PedvaxHIB vaccine or Comvax vaccine have been administered at 2 
and 4 months of age, the primary series of Hib has been completed. 
Question:  I have a 16 year old patient who received her first and second HPV vac-
cination last summer and now has come in for her final dose.  Since it has been so long 
between doses do I need to start over from the beginning of the series?  
Answer:  No, extended intervals (i.e. longer than the recommended spacing) are 
fine.  The patient does not need to have the series re-started.  Give the HPV dose today 
to complete the series, continuing where you left off.  Extended intervals between doses 
do not reduce final antibody concentrations, although protection might not be attained 
until the recommended number of doses has been administered. With the exception of 
oral typhoid vaccine, an interruption in the vaccination schedule does not require restart-
ing the entire series of a vaccine or toxoid or addition of extra doses.  
Question Corner 
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Changes to the 2008 Childhood Immunization Schedule, continued 
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toxoids and acellular pertussis 
vaccine (Td/Tdap) catch-up schedule 
for persons aged 7-18 years who 
received their first dose before age 12 
months now indicates that these 
youths should receive 4 doses, with 
at least 4 weeks (not 8 weeks) 
between doses 2 and 3.  
• The catch-up bars for hepatitis B and 
Haemophilus influenzae  type b 
conjugate vaccine have been deleted 
on the routine schedule for persons 
aged 0-6 years. The figure title refers  
users to the catch-up schedule for 
patients who fall behind or start late 
with vaccinations.  
Included with this newsletter you will 
find a laminated copy of the child and 
adult schedules for 2008.  For questions 
regarding vaccine schedules call 1-800-
831-6293, ext. 2 for Terri Thornton, or 
ext. 7 for Bridget Konz.    
• For meningococcal vaccines, 
changes affect certain children aged 
2-10 years. Vaccinating with 
meningococcal conjugate vaccine 
(MCV4) is preferred to 
meningococcal polysaccharide   
vaccine (MPSV4) for children at 
increased risk for  meningococcal 
disease, including children who are 
traveling to, or residents of, countries 
in which the disease is 
hyperendemic or epidemic, children 
who have terminal complement 
component  deficiencies, and 
children who have anatomic or 
functional asplenia. The catch-up 
schedule for youths aged 13-18 
years has been updated. MPSV4 is 
an acceptable alternative for short-
term (i.e., 3-5 years) protection 
against meningococcal disease for 
persons aged 2-18 years. 
• The tetanus and diphtheria 
toxoids/tetanus and diphtheria  
Iowa Receives National  
Immunization Award 
The Iowa Department of Public Health’s Immunization Program accepted an award on behalf 
of Iowa healthcare providers at the National Immunization Conference in Atlanta, Georgia on March 
17, 2008. The award is the result of an increase in immunization rates as published in the National Immunization Survey (NIS). 
Iowa is receiving the award for having the second highest state increase in immunization rates for children 19-35 months 
of age from 2003 through 2006. 
Iowa’s immunization rate in that population increased by more than 15 percent, from 63.4 percent in 2003 to 78.9 percent in 2006. 
The national immunization rate is 77 percent.  “This award is the result of the work done by public and private healthcare 
providers throughout the state.” said Don Callaghan, Iowa’s Immunization Program manager. “It’s a demonstration of 
their commitment to the health of Iowa children.” 
The NIS was established to provide an on-going, consistent data set for analyzing vaccination levels among young children in the 
U.S. The data gathered helps identify groups at risk of vaccine-preventable diseases, aids in the evaluation of the effectiveness of 
vaccine programs and ultimately assists in efforts to increase vaccinations.  
This award is a great refection of the hard work you do for the children and families of Iowa every day—Thank you! 
There is a correction to the HPV       
vaccine regimen in the Catch-up             
Immunization Schedule.  
The entry to HPV vaccine was changed to: 
 Dose 1 to 2                 Dose 2 to 3 
 4 weeks                      12 weeks   
  (and 24 weeks after the 
  first dose) 
This means that the third dose needs to be 
administered not earlier than 24 weeks 
from the first dose.  The minimum intervals 
between dose one and dose two as well 
as between dose two and dose three re-
main unchanged. The corrected Catch-up 
Schedule may be found at: 
http://www.cdc.gov/vaccines/recs/schedule
s/child-schedule.htm#catchup 
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Federal Vaccine Injury Case 
On March 13, CDC released interim editions of the VISs for MMR vac-
cine and varicella vaccine. The interim VIS for MMR vaccine replaces 
the previous edition dated 1/15/03; the interim VIS for varicella vaccine 
replaces the previous edition dated 1/10/07. 
 
The interim VISs for MMR vaccine and varicella vaccine have been 
updated to incorporate information about measles-mumps-rubella-
varicella (MMRV) vaccine. This includes information about the in-
creased rates of certain adverse events such as febrile seizures after 
MMRV vaccine administration.  
 
When giving MMRV vaccine, the new interim VISs should be used. 
When giving MMR vaccine or varicella vaccine separately, the pre-
viously published VISs may be used until stocks are depleted.  
 
For complete details on the VISs log onto the following Web sites: 
Interim VIS for MMR vaccine from the CDC Web site: 
http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-mmr.pdf  
 
Interim VIS for varicella vaccine from the CDC Web site:  
http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-varicella.pdf 
Providers may be asked about recent media coverage of the settlement 
of a federal vaccine injury case.  This case could cause confusion and 
hesitation of parents to have their children vaccinated, CDC continues to 
share on-line information and materials with partners concerning the 
vaccine injury case being discussed in the news. Information was re-
cently posted on mitochondrial disease and autism on CDC's Autism 
Web site. Links to more websites with resources pertaining to this case 
are listed below: 
• Transcript of CDC, NIH and NVPO Telebriefing on Vaccine Safety: 
http://www.cdc.gov/od/oc/media/transcripts/2008/t080307.htm 
•  Health Resources and Services Administration (HRSA) Statement 
on Autism and the Vaccine Injury Program: 
http://newsroom.hrsa.gov/releases/2008/vaccinestatement.htm 
• The National Vaccine Injury Compensation Program (VICP) Web-
site: http://www.hrsa.gov/vaccinecompensation/ 
• The US Court of Federal Claims, Office of Special Masters Website: 
http://www.uscfc.uscourts.gov/vaccine-programoffice-special-
masters 
• CDC's Vaccine Safety Website: http://www.cdc.gov/od/science/iso/ 
Upcoming Immunization 
Events to Celebrate  
National Infant Immunization Week:  
April 19-26, 2008 
http://www.cdc.gov/vaccines/events/niiw/default.htm 
World Hepatitis Day 
May 19, 2008  
http://www.nvhr.org/news/index.htm 
National Immunization Awareness Month 
August 2008 
http://www.cdc.gov/vaccines/events/niam/default.htm 
MMR and Varicella Vaccine VIS Updates April 12, 2005, 
marks the 50th     
anniversary of the 
first polio vaccine.   
April 12, 1955, was a unique 
moment in our contemporary culture. That date cul-
minated more than 17 years of research that led to 
the licensure of the first poliovirus vaccine. The vac-
cine breakthrough was driven by Jonas Salk and his 
team of scientists at the University of Pittsburgh and 
the pioneering field trials led by Thomas Francis Jr. 
at the University of Michigan. The research was 
funded by the National Foundation for Infantile Pa-
ralysis, today known as the March of Dimes. 
The fight against polio brought together communities 
in a national collaboration that at that time was the 
largest human cooperative effort in history. In the 
days leading up to the vaccine's approval, children 
in communities across the United States participated 
in the field trials as America's "Polio Pioneers."  
Thousands of health-care workers and lay people 
volunteered their time to assist with the vaccine field 
trials, the largest ever in United States history. Mil-
lions of Americans participated by raising funds in 
their communities to support the larger research 
effort and a single goal: victory over polio.  To read 
more about this historic anniversary go to: 
http://www.cdc.gov/vaccines/events/polio-vacc-50th/default.htm 
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Integration of Adult Vaccines into Routine Care  
New data released by CDC paint a 
disappointing picture of adult immuni-
zation against serious infectious dis-
eases in the United States. In addition, 
a new consumer survey 
shows the vast majority of 
adult Americans lack aware-
ness of vaccines and the 
severity of infectious dis-
eases. 
An expert panel discussed 
the data at a press confer-
ence held by the National Foundation 
for Infectious Diseases (NFID), which 
called for increased use of vaccines in 
adults to reduce needless illness and 
deaths associated with infectious dis-
eases. 
CDC's National Immunization Survey 
shows only 2.1 percent of  adults 18 to 
64 years of age are immunized against 
tetanus- diphtheria-whooping cough. 
Immunization to prevent shingles 
among people 60 and over was only 
1.9 percent. Vaccine coverage for the 
prevention of HPV (human papillomavi-
rus) among women 18 to 26 is about 
10 percent. In addition, influenza and 
pneumococcal vaccination rates for the 
elderly are well below the 90 percent 
national target rates. 
"Routine immunization of children in 
the United States has saved hundreds 
of thousands of lives and prevented 
millions of cases of disease, but vac-
cines are not just for children," said 
Anne  Schuchat, MD, director of the 
CDC's National Center for Immuniza-
tion and Respiratory Diseases. "These 
new data show there are not yet very 
many adults taking full advantage of 
the great advancements in prevention 
that have been made in the past few 
years." 
 "There are now 17 diseases that can 
be prevented from vaccines given to 
children, teens and adults. 
Several vaccines, including 
three fairly new ones li-
censed since 2005, are 
recommended specifically 
for the adult years. By skip-
ping vaccination, people 
are leaving themselves 
needlessly vulnerable to 
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“We are extremely fortunate in this 
country to have safe and effective 
vaccines available, but we have to 
use them better."  Dr. Anne Schuchat,  
Director of the CDC's National Center for          
Immunization and Respiratory Diseases 
Ordering Immunization Print Materials 
On Line! 
The Immunization Program has updated our Web page to in-
clude on-line ordering of our printed materials.   
With our new on-line ordering process you can preview items 
before placing an order, print single copies, or order multiple 
copies.  Some products have quantity limits; however, if addi-
tional quantities of a product  are needed please contact 
Bridget Konz at Bkonz@idph.state.ia.us or 1-800-831-6293, 
ext. 7.  
All brochures, posters, and printed documents are offered at 
no cost to your clinic and can be accessed by logging onto our 
Web page: http://www.idph.state.ia.us/adper/immunization_products.asp.   
CDC’s 2008 Pink Book 
In 2008, the CDC will publish the 2nd printing of 
the Epidemiology and Prevention of Vaccine-
Preventable Diseases, 10th Edition (also 
known as the “Pink Book”).   
Essentially the content between the first and second printings 
will be the same, with a few minor formatting changes.  Typi-
cally the CDC publishes the Pink Book each year; however 
with so few changes anticipated another full edition was not 
necessary. The cost of a Pink book is $32.00.   Information on 
ordering a Pink Book, or downloading chapters, can be found 
at the CDC Web page: 
http://www.cdc.gov/vaccines/pubs/pinkbook/default.htm 
significant illness, long-term suffering, and 
even death," said Dr. Schuchat. " 
Immunization is recommended for U.S. 
adults to protect them against chickenpox, 
diphtheria, hepatitis A, hepatitis B, human  
papillomavirus/cervical cancer (HPV), 
influenza, measles, meningococcal dis-
ease, mumps, pertussis (whooping 
cough), pneumococcal disease, rubella, 
shingles, and tetanus.  
"Combined, these infectious diseases kill 
more Americans annually than either 
breast cancer, HIV/AIDS, or traffic acci-
dents," said William Schaffner, MD, vice 
president of NFID and chairman of the 
Department of Preventive Medicine at 
Vanderbilt University School of Medicine.  
"A concerted effort is needed to raise 
adult immunization rates," said Dr. Schaff-
ner. "The important thing to remember is 
that deaths and illness associated with 
these infections are largely avoidable 
through vaccination." 
Continuing Education Opportunity 
The CDC website recently posted an interactive training pro-
gram for primary care practitioners. "Increasing Adult Vaccina-
tion Rates: WhatWorks" gives each participant the opportunity 
to work through a case study in a setting similar to the one the 
participant works in. Continuing Education credits are avail-
able.   To learn more about the program, go to:  
http://www2.cdc.gov/vaccines/ed/whatworks/index.html 
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Along with the Recommended Child-
hood Vaccination Schedule, each per-
son administering vaccines should be 
familiar with the Catch-up Immunization 
Schedule (also called the minimum in-
terval chart).   
Providers should adhere as closely as 
possible to recommended vaccination 
schedules; however, in certain circum-
stances administering doses of vaccine 
at shorter than the recommended inter-
vals might be necessary (such as when 
the child is behind schedule and needs 
to be brought up-to-date as quickly as 
possible or when international travel is 
impending).  
In these situations, an accelerated 
schedule can be implemented that uses 
intervals between doses shorter than 
those recommended for routine vaccina-
tion. When using the Catch-up Immuni-
zation Schedule, vaccine doses should 
not be administered at intervals less 
than the listed minimum intervals or ear-
lier than the minimum age. 
In clinical practice, vaccine doses occa-
sionally are administered at intervals 
less than the minimum interval or at 
ages younger than the minimum age. 
Doses administered too close together 
or at too young an age can lead to a 
suboptimal immune response.  
However, administering a dose a limited 
number of days earlier than the mini-
mum interval or age is unlikely to have a 
substantially negative effect on the im-
mune response to that dose. Therefore, 
ACIP recommends that vaccine doses 
administered 4 or fewer days before the 
minimum interval or age be counted as 
valid. However, because of its unique 
schedule, this recommendation does 
not apply to the rabies vaccine.  
Iowa Administrative Code Chapter 
641.7 also allows for this “grace period” 
of 4 days or fewer for vaccine doses as 
it relates to licensed day care and 
school immunization requirements.  
Doses administered 5 or more days 
earlier than the minimum interval or age 
of any vaccine should not be counted 
as valid doses and should be repeated 
as age-appropriate. The repeat dose 
should be spaced 4 or more weeks after 
the invalid dose (see catch-up Immuni-
zation Schedule) 
Example 1: If Haemophilus influenzae 
type b (Hib) doses one and two were 
administered only 2 weeks apart, be-
cause the minimum interval from dose 
one to dose two is 4 weeks, dose two is 
invalid and should be repeated. The 
repeat dose should be administered 4 
or more weeks after the invalid (second) 
dose.  The repeat dose would be 
counted as the second valid dose.  
Example 2: If the first dose of varicella 
vaccine were administered at age 10 
months, the repeat dose would be ad-
ministered no earlier than the child’s 
first birthday (Rational: the minimum 
age for varicella vaccine is 12 months of 
age). If the first dose of varicella vac-
cine were administered at age 11 
months and 2 weeks, the repeat dose 
could be administered 2 weeks after the 
first birthday (Rational: the minimum age 
for varicella vaccine is 12 months of age.  
The dose was administered 2 weeks be-
fore the 12 month birthday; therefore, it 
must be repeated.  Furthermore, the re-
peat dose must be at least 28 days, or 4 
weeks, from the invalid dose given at 11 
months 2 weeks.) 
Certain vaccines produce increased rates 
of local or systemic reactions in certain 
recipients when administered too fre-
quently (e.g., adult Td; pediatric DT; teta-
nus toxoid; and DTaP and Tdap). Such 
reactions might result from formation of 
antigen-antibody complexes. Keeping 
complete records, maintaining patient his-
tories, and adhering to recommended 
schedules can decrease the incidence of 
such reactions without adversely affecting 
immunity. 
For questions regarding minimum interval 
spacing please contact 1-800-831-6293, 
ext. 2 for Terri Thornton, or ext. 7 for 
Bridget Konz..  Source MMWR: December 1, 
2006 / Vol. 55 / No. RR-15 
http://www.cdc.gov/mmwr/PDF/rr/rr5515.pdf  
Vaccine Interval Spacing is Imperative Fo c u s  o n  t h e  I s s u e :  
2008 Catch Up Immunization Schedule 
Do you want to have the Immunization Update Newsletter sent to you direectly? Do you know someone who would?  Send your 
name and mailing address to Bkonz@idph.state.ia.us and we will sign you up—it’s as easy as that!  The Immunization Update is also available 
on our Web page at: www.idph.state.ia.us/adper/immunization.asp It’s a great way to send the Newsletter on to others in your facility or com-
munity. 
